Literature DB >> 18699955

A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole.

S G Schorr1, C J Slooff, R Postema, W Van Oven, M Schilthuis, R Bruggeman, K Taxis.   

Abstract

OBJECTIVE: To investigate the feasibility of switching overweight schizophrenic patients to aripiprazole and to assess the impact of 12 months of aripiprazole treatment on weight in routine practice.
METHOD: This was a non-controlled cohort study in overweight schizophrenic patients. Data were collected before treatment with aripiprazole was started and at 12-month follow-up.
RESULTS: A total of 53 patients were included; of these 55% continued using aripiprazole for 12 months. Aripiprazole treatment for 12 months (P = 0.027) and stopping clozapine or olanzapine treatment (P = 0.038) predicted weight loss (> or =3 kg). Patients receiving aripiprazole monotherapy (n = 16, mean -3.0 kg) had similar weight loss than patients receiving aripiprazole in addition to another antipsychotic drug (n = 13, mean -4.4 kg).
CONCLUSION: In routine practice once aripiprazole treatment was started, more than half of the patients remained on aripiprazole and most of them lost weight. Adding aripiprazole to clozapine gave similar weight loss as monotherapy with aripiprazole.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18699955     DOI: 10.1111/j.1600-0447.2008.01232.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  5 in total

1.  A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder.

Authors:  Roger S McIntyre; Susan L McElroy; James M Eudicone; Robert A Forbes; Berit X Carlson; Ross A Baker
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  Metabolic syndrome in people with schizophrenia: a review.

Authors:  Marc DE Hert; Vincent Schreurs; Davy Vancampfort; Ruud VAN Winkel
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

3.  Switching to aripiprazole as a strategy for weight reduction: a meta-analysis in patients suffering from schizophrenia.

Authors:  Yoram Barak; Dov Aizenberg
Journal:  J Obes       Date:  2010-08-25

4.  Reversibility of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis.

Authors:  Helene Speyer; Casper Westergaard; Nikolai Albert; Mette Karlsen; Anne Emilie Stürup; Merete Nordentoft; Jesper Krogh
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-28       Impact factor: 5.555

5.  A systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: focus on aripiprazole.

Authors:  Salvatore Gentile
Journal:  Neuropsychiatr Dis Treat       Date:  2009-04-08       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.